Literature DB >> 1687171

The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics.

E K Rowinsky1, R C Donehower.   

Abstract

Although there has been a rapid expansion of the number of classes of compounds with antineoplastic activity, few have played a more vital role in the curative and palliative treatment of cancers than the antimicrotubule agents. Although the vinca alkaloids have been the only subclass of antimicrotubule agents that have had broad experimental and clinical applications in oncologic therapeutics over the last several decades, the taxanes, led by the prototypic agent taxol, are emerging as another very active class of antimicrotubule agents. After briefly reviewing the mechanisms of antineoplastic action and resistance, this article comprehensively reviews the clinical pharmacology, therapeutic applications, and clinical toxicities of selected antimicrotubule agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1687171     DOI: 10.1016/0163-7258(91)90086-2

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  49 in total

1.  Novel suicide ligands of tubulin arrest cancer cells in S-phase.

Authors:  A Davis; J D Jiang; K M Middleton; Y Wang; I Weisz; Y H Ling; J G Bekesi
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

Review 2.  Advanced non-small cell lung carcinoma: the emerging role of docetaxel.

Authors:  C J Langer
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 3.  Is signal transduction modulated by an interaction between heterotrimeric G-proteins and tubulin?

Authors:  R Ravindra
Journal:  Endocrine       Date:  1997-10       Impact factor: 3.633

4.  Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells.

Authors:  K Ye; Y Ke; N Keshava; J Shanks; J A Kapp; R R Tekmal; J Petros; H C Joshi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

5.  Development of a new benzophenone-diketopiperazine-type potent antimicrotubule agent possessing a 2-pyridine structure.

Authors:  Yoshiki Hayashi; Haruka Takeno; Takumi Chinen; Kyohei Muguruma; Kohei Okuyama; Akihiro Taguchi; Kentaro Takayama; Fumika Yakushiji; Masahiko Miura; Takeo Usui; Yoshio Hayashi
Journal:  ACS Med Chem Lett       Date:  2014-07-23       Impact factor: 4.345

6.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.

Authors:  M A Jordan; R J Toso; D Thrower; L Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

7.  Cytotoxic Activity and Three-Dimensional Quantitative Structure Activity Relationship of 2-Aryl-1,8-naphthyridin-4-ones.

Authors:  Yong Jin Kim; Eun Ae Kim; Mi Lyang Chung; Chaeuk Im
Journal:  Korean J Physiol Pharmacol       Date:  2009-12-31       Impact factor: 2.016

8.  Mitotic slippage in non-cancer cells induced by a microtubule disruptor, disorazole C1.

Authors:  Fengfeng L Xu; Youssef Rbaibi; Kirill Kiselyov; John S Lazo; Peter Wipf; William S Saunders
Journal:  BMC Chem Biol       Date:  2010-02-11

9.  Therapeutic anticancer efficacy of a synthetic diazonamide analog in the absence of overt toxicity.

Authors:  Noelle S Williams; Anthony W G Burgett; Ashley S Atkins; Xiaodong Wang; Patrick G Harran; Steven L McKnight
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-07       Impact factor: 11.205

10.  Design and synthesis of 2-(3-benzo[b]thienyl)-6,7-methylenedioxyquinolin-4-one analogues as potent antitumor agents that inhibit tubulin assembly.

Authors:  Yu-Hsun Chang; Mei-Hua Hsu; Sheng-Hung Wang; Li-Jiau Huang; Keduo Qian; Susan L Morris-Natschke; Ernest Hamel; Sheng-Chu Kuo; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.